CDC Raises Awareness of Emerging Public Health Risks Associated with Tianeptine

PUBLISHED: Aug 3, 2018
Relevant to: All Healthcare Organizations

Tianeptine (marketed as Coaxil or Stablon) is an atypical tricyclic drug used an antidepressant drug in Europe, Asia, and Latin America. In the United States, it is not approved by the Food and Drug Administration (FDA) for medical use, however, it is readily available for purchase online as a dietary supplement or research chemical. Several online discussion forums among users describe the euphoregenic effects of tianeptine.

In light of the ongoing U.S. opioid epidemic, any emerging trends in drugs with opioid-like effects raise concerns about potential abuse and public health safety. Clinical effects of tianeptine abuse and withdrawal can mimic opioid toxicity and withdrawal.

Tianeptine exposure calls to U.S. poison control centers increased during 2014–2017, suggesting a possible emerging public health risk. The associated health effects included neurologic, cardiovascular, and gastrointestinal signs and symptoms, with some effects mimicking opioid toxicity and withdrawal.

Health care providers and public health officials need to be vigilant for potential cases of tianeptine exposure and, when applicable, report adverse effects to the FDA MedWatch reporting system.

Clinicians and other health care providers can contact their local poison control center by telephone at 1-800-222-1222 for clinical guidance as needed.

The U.S. Centers for Disease Control and Prevention has new continuing education about Tianeptine, a link to which is provided below.

Want to read the full alert and receive alert emails?

Browse Additional Alerts